Viatris, Inc. (DE:VIA)
NASDAQ:VIA
VIA Stock Chart & Stats
€12.15
€0.08(0.69%)
At close: 4:00 PM EST
€12.15
€0.08(0.69%)
Day’s Range― - ―
52-Week Range€7.48 - €14.99
Previous CloseN/A
Volume947.00
Average Volume (3M)2.54K
Market Cap
€16.07B
Enterprise Value€31.48B
Total Cash (Recent Filing)€1.80B
Total Debt (Recent Filing)€14.34B
Price to Earnings (P/E)―
Beta0.68
Next Earnings
Aug 10, 2026EPS Estimate
0.52Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding1,164,552,600
10 Day Avg. Volume965
30 Day Avg. Volume2,544
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.99
Price to Sales (P/S)1.02
P/FCF Ratio7.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€15.07Price Target Upside24.07% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)2.12
Revenue Forecast (FY)€12.71B
Bulls Say, Bears Say
Bulls Say
Strong Cash Generation & Capital FlexibilitySustained positive operating and free cash flow provides durable financial flexibility to fund launches, pay dividends, pursue M&A, and service debt without relying on new capital. This strengthens resilience through industry cycles and supports strategic reinvestment over the next 2–6 months and beyond.
Robust Late-stage Pipeline And Regulatory CatalystsA concentrated set of late‑stage programs and pending approvals offers structural upside by diversifying revenue into higher‑value products and complex generics. Successful approvals and launches can sustainably improve product mix and margins versus commoditized generics over the medium term.
Restructuring Driving Cost Savings And Margin DisciplineA large, committed restructuring with multi‑year net cost savings improves operating leverage and margin durability. Realizing these savings should enhance adjusted EBITDA conversion and fund strategic priorities, making earnings less sensitive to short-term generic pricing shocks.
Bears Say
Negative And Volatile Reported ProfitabilityPersistent negative trailing‑twelve‑month net income and volatile margins indicate earnings quality issues. Even with strong cash flow, sustained reported losses limit retained earnings and ROE, constraining capital allocation choices and raising execution pressure to convert operational gains into consistent GAAP profitability.
Multi-year Revenue Drift And Generics CompetitionA secular downward revenue trend plus intense pricing competition in commoditized generics pressure sustainable top‑line growth and compresses margins. Structural headwinds in developed markets increase reliance on new launches and international growth to reverse the decline over the medium term.
Dependence On Successful Launches And Regulatory TimingBusiness momentum and margin improvement hinge on multiple regulatory approvals and commercial rollouts. Delays, adverse decisions, or poor launch uptake would materially weaken projected revenue and cash flow trajectories, making near‑term recovery outcomes highly execution‑sensitive.
Viatris News
VIA FAQ
What was Viatris, Inc.’s price range in the past 12 months?
Viatris, Inc. lowest stock price was €7.48 and its highest was €14.99 in the past 12 months.
What is Viatris, Inc.’s market cap?
Viatris, Inc.’s market cap is €16.07B.
When is Viatris, Inc.’s upcoming earnings report date?
Viatris, Inc.’s upcoming earnings report date is Aug 10, 2026 which is in 65 days.
How were Viatris, Inc.’s earnings last quarter?
Viatris, Inc. released its earnings results on May 07, 2026. The company reported €0.508 earnings per share for the quarter, beating the consensus estimate of €0.432 by €0.076.
Is Viatris, Inc. overvalued?
According to Wall Street analysts Viatris, Inc.’s price is currently Undervalued.
Does Viatris, Inc. pay dividends?
Viatris, Inc. does not currently pay dividends.
What is Viatris, Inc.’s EPS estimate?
Viatris, Inc.’s EPS estimate is 0.52.
How many shares outstanding does Viatris, Inc. have?
Viatris, Inc. has 1,164,552,600 shares outstanding.
What happened to Viatris, Inc.’s price movement after its last earnings report?
Viatris, Inc. reported an EPS of €0.508 in its last earnings report, beating expectations of €0.432. Following the earnings report the stock price went up 4.28%.
Which hedge fund is a major shareholder of Viatris, Inc.?
Currently, no hedge funds are holding shares in DE:VIA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Viatris Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€15.07 (24.07% Upside)
€15.07 (24.07% Upside)
Blogger Sentiment
Neutral
DE:VIA Sentiment 50%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth €117.7K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
92.40%
12-Months-Change
Fundamentals
Return on Equity
-1.97%
Trailing 12-Months
Asset Growth
-4.26%
Trailing 12-Months
Company Description
Viatris, Inc.
Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as offers biosimilars franchises, including Fulphila, Ogivri, Hulio, and SEMGLEE. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
VIA Company Deck
VIA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call portrayed solid operational performance and momentum: top-line revenue growth (3%), strong adjusted EBITDA expansion (10%), sizable China acceleration (+18%), meaningful pipeline progress with multiple upcoming regulatory catalysts, and robust cash flexibility (> $2.5B). These positives were tempered by regional softness (Europe, JANZ), supply constraints in lower-margin generics/ARV, ongoing regulatory timing uncertainty, and policy risk in China. On balance, the positives (broad-based execution, margin control, late-stage pipeline momentum and financial flexibility) outweigh the lowlights.View all DE:VIA earnings summariesVIA Net sales Breakdown
64.45% Brands
35.55% Generics
VIA Stock 12 Month Forecast
Average Price Target
€15.07
▲(24.07% Upside)
Technical Analysis
Dr Reddy's Laboratories
―
Perrigo Company
―
Teva Pharmaceutical
―
ANI Pharmaceuticals
―
Amneal Pharmaceuticals
―
Options Prices
Currently, No data available
---